Securities Code: 002099 Securities Abbreviation: Haixiang Pharmaceutical Announcement Number: 2026-041
Zhejiang Haixiang Pharmaceutical Co., Ltd. Repurchase Report
The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or material omissions.
Key Information Highlights
- Basic Information on Repurchase Zhejiang Haixiang Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") will use its own funds or self-raised funds to repurchase the Company's shares through centralized bidding transactions. The total repurchase amount will be no less than RMB 150 million (inclusive) and no more than RMB 300 million (inclusive). The repurchase price will not exceed RMB 8.55 per share (inclusive). Calculated based on the upper limit of the total repurchase amount of RMB 300 million and the upper limit of the repurchase price of RMB 8.55 per share, the estimated number of shares to be repurchased is approximately 35.08 million shares, accounting for about 2.17% of the Company's current total share capital. The specific repurchase amount and number of shares will be subject to the actual funds used and the number of shares repurchased upon completion of the repurchase. (Hereinafter referred to as the "Current Repurchase")
The implementation period for the repurchase of shares shall be within 12 months from the date the Board of Directors approves the repurchase plan. The repurchased shares will be used for equity incentives or employee stock ownership plans. If the Company fails to use the repurchased shares within 36 months after the completion of the share repurchase, the unutilized repurchased shares will be cancelled. If there are adjustments to national policies, the adjusted policies will apply.
-
Relevant Review Procedures The Company held the Fourth Meeting of the Eighth Board of Directors on June 22, 2026, and approved the "Proposal on the Repurchase of Shares." For details, please refer to the "Resolution Announcement of the Fourth Meeting of the Eighth Board of Directors" (Announcement Number: 2026-039) published by the Company in the Securities Times, China Securities Journal, and Juchao Information Network. In accordance with relevant laws and regulations and the "Articles of Association," this share repurchase plan falls within the scope of the Board of Directors' approval authority and does not require submission to the Company's shareholders' meeting for approval.
-
Opening of a Dedicated Repurchase Account
The Company has opened a dedicated securities account for repurchases with China Securities Depository and Clearing Corporation Limited Shenzhen Branch.
- Plans for Increase or Decrease in Holdings by Relevant Personnel The Company's directors, senior management, controlling shareholders, actual controllers, and their concerted parties have no definite plans to increase or decrease their holdings of the Company's shares during the repurchase period.